CF PharmTech (HKG:2652) said Chinese regulators had accepted its investigational new drug application to study ICF004 in clinical trials, according to a Hong Kong bourse filing Tuesday.
The medicine is intended as a treatment for progressive fibrosing interstitial lung disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.